Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Vocal fold hemorrhage in a CML patient after Glivec treatment.

Shim HS, Woo SH.

Acta Oncol. 2013 May;52(4):866-8. doi: 10.3109/0284186X.2012.728715. Epub 2012 Nov 15. No abstract available.

PMID:
23153030
2.

Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.

Dika E, Barisani A, Vaccari S, Fanti PA, Ismaili A, Patrizi A.

J Drugs Dermatol. 2013 May;12(5):512-3. No abstract available.

PMID:
23652942
3.

Management of the new patient with CML in chronic phase.

Marin D.

Curr Hematol Malig Rep. 2013 Mar;8(1):37-42. doi: 10.1007/s11899-012-0151-0. Review.

PMID:
23381448
4.

A patient of chronic myelogenous leukemia developing painful rash on feet.

Kumar P, Das NK, Sil A, Chakrabarti P.

J Postgrad Med. 2012 Oct-Dec;58(4):331-4. doi: 10.4103/0022-3859.105489. No abstract available.

5.

Multiple eruptive dermatofibromas related to imatinib treatment.

Llamas-Velasco M, Fraga J, Solano-López GE, Steegmann JL, García Diez A, Requena L.

J Eur Acad Dermatol Venereol. 2014 Jul;28(7):979-81. doi: 10.1111/jdv.12328. Epub 2013 Dec 10. No abstract available.

PMID:
24321053
6.

Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.

Khoo TL, Catalano A, Supple S, Chong L, Yeoh SC, Yeung S, Iland H.

Leuk Lymphoma. 2013 Jan;54(1):186-8. doi: 10.3109/10428194.2012.702904. Epub 2012 Aug 14. No abstract available.

PMID:
22712835
7.

Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.

Giona F, Mariani S, Gnessi L, Moleti ML, Rea M, De Vellis A, Marzella D, Testi AM, Foà R.

Haematologica. 2013 Mar;98(3):e25-7. doi: 10.3324/haematol.2012.067447. Epub 2012 Sep 14. No abstract available.

8.
9.

[Standard therapy for chronic myelogenous leukemia].

Kimura S.

Rinsho Ketsueki. 2012 Oct;53(10):1571-80. Review. Japanese. No abstract available.

PMID:
23037729
10.

Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.

Mabed M, Elhefni AM, Damnhouri G.

Leuk Lymphoma. 2012 Nov;53(11):2310-1. doi: 10.3109/10428194.2012.680452. Epub 2012 Apr 30. No abstract available.

PMID:
22462614
11.

[Chronic myeloid leukemia treatment and human immunodeficiency virus infection].

Campillo-Recio D, Perez-Rodriguez L, Yebra E, Cervero-Jimenez M.

Rev Clin Esp (Barc). 2014 May;214(4):231-2. doi: 10.1016/j.rce.2014.01.025. Epub 2014 Feb 22. Spanish. No abstract available.

PMID:
24564991
12.

Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?

Tefferi A.

Leukemia. 2013 Sep;27(9):1939-40. doi: 10.1038/leu.2013.112. Epub 2013 Apr 22. No abstract available.

13.

Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.

Yamazaki R, Okamoto S, Chen CK, Tada S, Saito H, Shibata R, Sakamoto M, Mori T, Ikeda Y.

Leuk Lymphoma. 2006 Jul;47(7):1427-30. No abstract available.

PMID:
16923586
14.

Imatinib-induced Stevens-Johnsons syndrome.

Jha P, Himanshu D, Jain N, Singh AK.

BMJ Case Rep. 2013 Jan 23;2013. pii: bcr2012007926. doi: 10.1136/bcr-2012-007926.

15.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP.

Blood. 2013 Jul 25;122(4):515-22. doi: 10.1182/blood-2013-02-483750. Epub 2013 May 23.

16.

STI-571 (Gleevec) in the treatment of chronic myeloid leukaemia.

Kumar L, Kumari M, Menon H.

Natl Med J India. 2002 Sep-Oct;15(5):298. No abstract available. Erratum in: Natl Med J India. 2002 Nov-Dec;15(6):350..

PMID:
12502149
17.

[Imatinib plasma levels in the management of cutaneous side effects induced by imatinib (Glivec®): 2 case reports].

Trabelsi S, Gaïes E, Sraïri S, Sahnoun R, Daghfous R, Lakhal M, El Aïdli S, Klouz A.

Ann Biol Clin (Paris). 2013 Mar-Apr;71(2):203-6. doi: 10.1684/abc.2013.0795. French.

18.

Imatinib-associated hyperpigmentation, a side effect that should be recognized.

Mcpherson T, Sherman V, Turner R.

J Eur Acad Dermatol Venereol. 2009 Jan;23(1):82-3. doi: 10.1111/j.1468-3083.2008.02706.x. Epub 2008 Apr 1. No abstract available.

PMID:
18384557
19.

Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.

Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A.

Leukemia. 2003 Feb;17(2):465-7. No abstract available.

PMID:
12592350
20.

[Chronic myelogenous leukemia: management of treatment-related adverse events].

Takahashi N.

Rinsho Ketsueki. 2012 Oct;53(10):1581-8. Review. Japanese. No abstract available.

PMID:
23037730

Supplemental Content

Support Center